Esophageal adenocarcinoma (EAC) is highly mutated and molecularly heterogeneous. The number of cell lines available for study is limited and their genome has been only partially characterized. The availability of an accurate annotation of their mutational landscape is crucial for accurate experimental design and correct interpretation of genotype-phenotype findings. We performed high coverage, paired end whole genome sequencing on eight EAC cell lines-ESO26, ESO51, FLO-1, JH-EsoAd1, OACM5.1 C, OACP4 C, OE33, SK-GT-4-all verified against original patient material, and one esophageal high grade dysplasia cell line, CP-D. We have made available the aligned sequence data and report single nucleotide variants (SNVs), small insertions and deletio...
Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have thus far been d...
Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers world wide and the fourt...
Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have thus far been d...
Esophageal adenocarcinoma (EAC) is highly mutated and molecularly heterogeneous. The number of cell ...
We applied whole-genome single-nucleotide polymorphism arrays to define a comprehensive genetic prof...
We applied whole-genome single-nucleotide polymorphism arrays to define a comprehensive genetic prof...
Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have thus far been d...
The scientific community has avoided using tissue samples from patients that have been exposed to sy...
We applied whole-genome single-nucleotide polymorphism arrays to define a comprehensive genetic prof...
The molecular genetic relationship between esophageal adenocarcinoma (EAC) and its precursor lesion,...
The scientific community has avoided using tissue samples from patients that have been exposed to sy...
The scientific community has avoided using tissue samples from patients that have been exposed to sy...
Esophageal adenocarcinoma (EAC) is a poor-prognosis cancer type with rapidly rising incidence. Under...
INTRODUCTION: Our study aimed at investigating tumor heterogeneity in esophageal adenocarcinoma (E...
Abstract: Simple Summary The molecular heterogeneity of esophageal adenocarcinoma (EAC), a severe ma...
Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have thus far been d...
Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers world wide and the fourt...
Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have thus far been d...
Esophageal adenocarcinoma (EAC) is highly mutated and molecularly heterogeneous. The number of cell ...
We applied whole-genome single-nucleotide polymorphism arrays to define a comprehensive genetic prof...
We applied whole-genome single-nucleotide polymorphism arrays to define a comprehensive genetic prof...
Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have thus far been d...
The scientific community has avoided using tissue samples from patients that have been exposed to sy...
We applied whole-genome single-nucleotide polymorphism arrays to define a comprehensive genetic prof...
The molecular genetic relationship between esophageal adenocarcinoma (EAC) and its precursor lesion,...
The scientific community has avoided using tissue samples from patients that have been exposed to sy...
The scientific community has avoided using tissue samples from patients that have been exposed to sy...
Esophageal adenocarcinoma (EAC) is a poor-prognosis cancer type with rapidly rising incidence. Under...
INTRODUCTION: Our study aimed at investigating tumor heterogeneity in esophageal adenocarcinoma (E...
Abstract: Simple Summary The molecular heterogeneity of esophageal adenocarcinoma (EAC), a severe ma...
Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have thus far been d...
Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers world wide and the fourt...
Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have thus far been d...